Clinical features of two exenatide treatments given twice daily or once weekly for incretin therapy

Weekly exenatide decreases HbA1c more than exenatide administered twice daily.

• Both exenatide formulations target the same receptors but have different effects on blood sugar levels.
• Exenatide administered twice daily shows a hypoglycemic effect comparable to other type 2 diabetes treatments and promotes significant weight loss with a low risk of causing low blood sugar.
• Weekly exenatide reduces HbA1c levels similarly to liraglutide and more than exenatide BID, glargine, biphasic insulin, sitagliptin, and pioglitazone.
• Weekly administration of exenatide maintains weight loss but is associated with gastrointestinal discomfort and injection site induration.

Simplified